Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

Overexpression of PDGFRA cooperates with loss of NF1 and p53 to accelerate the molecular pathogenesis of malignant peripheral nerve sheath tumors.

Ki DH, He S, Rodig S, Look AT.

Oncogene. 2017 Feb 23;36(8):1058-1068. doi: 10.1038/onc.2016.269. Epub 2016 Aug 1.

2.

Zebrafish neurofibromatosis type 1 genes have redundant functions in tumorigenesis and embryonic development.

Shin J, Padmanabhan A, de Groh ED, Lee JS, Haidar S, Dahlberg S, Guo F, He S, Wolman MA, Granato M, Lawson ND, Wolfe SA, Kim SH, Solnica-Krezel L, Kanki JP, Ligon KL, Epstein JA, Look AT.

Dis Model Mech. 2012 Nov;5(6):881-94. doi: 10.1242/dmm.009779. Epub 2012 Jul 5.

3.

Spatially- and temporally-controlled postnatal p53 knockdown cooperates with embryonic Schwann cell precursor Nf1 gene loss to promote malignant peripheral nerve sheath tumor formation.

Hirbe AC, Dahiya S, Friedmann-Morvinski D, Verma IM, Clapp DW, Gutmann DH.

Oncotarget. 2016 Feb 16;7(7):7403-14. doi: 10.18632/oncotarget.7232.

4.

TAGLN expression is upregulated in NF1-associated malignant peripheral nerve sheath tumors by hypomethylation in its promoter and subpromoter regions.

Park GH, Lee SJ, Yim H, Han JH, Kim HJ, Sohn YB, Ko JM, Jeong SY.

Oncol Rep. 2014 Oct;32(4):1347-54. doi: 10.3892/or.2014.3379. Epub 2014 Aug 4.

5.

Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis.

Kazmi SJ, Byer SJ, Eckert JM, Turk AN, Huijbregts RP, Brossier NM, Grizzle WE, Mikhail FM, Roth KA, Carroll SL.

Am J Pathol. 2013 Mar;182(3):646-67. doi: 10.1016/j.ajpath.2012.11.017. Epub 2013 Jan 13.

6.

PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor.

Perrone F, Da Riva L, Orsenigo M, Losa M, Jocollè G, Millefanti C, Pastore E, Gronchi A, Pierotti MA, Pilotti S.

Neuro Oncol. 2009 Dec;11(6):725-36. doi: 10.1215/15228517-2009-003.

7.

NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.

Park HJ, Lee SJ, Sohn YB, Jin HS, Han JH, Kim YB, Yim H, Jeong SY.

Int J Oncol. 2013 Feb;42(2):657-66. doi: 10.3892/ijo.2012.1751. Epub 2012 Dec 24.

PMID:
23292448
8.

The promise of signal transduction in genetically driven sarcomas of the nerve.

Kim A, Pratilas CA.

Exp Neurol. 2018 Jan;299(Pt B):317-325. doi: 10.1016/j.expneurol.2017.08.014. Epub 2017 Aug 30. Review.

PMID:
28859862
9.

Loss of atrx cooperates with p53-deficiency to promote the development of sarcomas and other malignancies.

Oppel F, Tao T, Shi H, Ross KN, Zimmerman MW, He S, Tong G, Aster JC, Look AT.

PLoS Genet. 2019 Apr 10;15(4):e1008039. doi: 10.1371/journal.pgen.1008039. eCollection 2019 Apr.

10.

Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs).

Upadhyaya M, Kluwe L, Spurlock G, Monem B, Majounie E, Mantripragada K, Ruggieri M, Chuzhanova N, Evans DG, Ferner R, Thomas N, Guha A, Mautner V.

Hum Mutat. 2008 Jan;29(1):74-82.

PMID:
17960768
11.

Translationally controlled tumor protein is a novel biological target for neurofibromatosis type 1-associated tumors.

Kobayashi D, Hirayama M, Komohara Y, Mizuguchi S, Wilson Morifuji M, Ihn H, Takeya M, Kuramochi A, Araki N.

J Biol Chem. 2014 Sep 19;289(38):26314-26. doi: 10.1074/jbc.M114.568253. Epub 2014 Aug 4.

12.

Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.

Gottfried ON, Viskochil DH, Couldwell WT.

Neurosurg Focus. 2010 Jan;28(1):E8. doi: 10.3171/2009.11.FOCUS09221.

PMID:
20043723
13.
14.
15.

The role of neurofibromin in N-Ras mediated AP-1 regulation in malignant peripheral nerve sheath tumors.

Kraniak JM, Sun D, Mattingly RR, Reiners JJ Jr, Tainsky MA.

Mol Cell Biochem. 2010 Nov;344(1-2):267-76. doi: 10.1007/s11010-010-0551-1. Epub 2010 Aug 1.

16.

Neuregulin-1 overexpression and Trp53 haploinsufficiency cooperatively promote de novo malignant peripheral nerve sheath tumor pathogenesis.

Brosius SN, Turk AN, Byer SJ, Brossier NM, Kohli L, Whitmire A, Mikhail FM, Roth KA, Carroll SL.

Acta Neuropathol. 2014 Apr;127(4):573-91.

17.

The 4q12 amplicon in malignant peripheral nerve sheath tumors: consequences on gene expression and implications for sunitinib treatment.

Zietsch J, Ziegenhagen N, Heppner FL, Reuss D, von Deimling A, Holtkamp N.

PLoS One. 2010 Jul 29;5(7):e11858. doi: 10.1371/journal.pone.0011858.

18.

RAS/MEK-independent gene expression reveals BMP2-related malignant phenotypes in the Nf1-deficient MPNST.

Sun D, Haddad R, Kraniak JM, Horne SD, Tainsky MA.

Mol Cancer Res. 2013 Jun;11(6):616-27. doi: 10.1158/1541-7786.MCR-12-0593. Epub 2013 Feb 19.

19.

Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.

Hirbe AC, Kaushal M, Sharma MK, Dahiya S, Pekmezci M, Perry A, Gutmann DH.

Cancer. 2017 Apr 1;123(7):1194-1201. doi: 10.1002/cncr.30455. Epub 2016 Nov 22.

20.

Supplemental Content

Support Center